stoxline Quote Chart Rank Option Currency Glossary
  
Heron Therapeutics, Inc. (HRTX)
3.45  0.18 (5.5%)    05-30 16:00
Open: 3.28
High: 3.515
Volume: 2,534,697
  
Pre. Close: 3.27
Low: 3.265
Market Cap: 520(M)
Technical analysis
2024-05-30 4:42:06 PM
Short term     
Mid term     
Targets 6-month :  4.18 1-year :  4.89
Resists First :  3.58 Second :  4.18
Pivot price 3.2
Supports First :  2.77 Second :  2.26
MAs MA(5) :  3.4 MA(20) :  3.09
MA(100) :  2.69 MA(250) :  1.83
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  76.5 D(3) :  79.5
RSI RSI(14): 65
52-week High :  3.58 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HRTX ] has closed below upper band by 26.5%. Bollinger Bands are 37.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.52 - 3.55 3.55 - 3.57
Low: 3.21 - 3.24 3.24 - 3.26
Close: 3.4 - 3.45 3.45 - 3.49
Company Description

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Headline News

Thu, 30 May 2024
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too - Simply Wall St

Thu, 30 May 2024
Victory Capital Management Inc. Acquires 4617 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Thu, 30 May 2024
Franklin Resources Inc. Sells 553315 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Tue, 28 May 2024
How Much Did Heron Therapeutics'(NASDAQ:HRTX) Shareholders Earn From Share Price Movements Over The Last ... - Yahoo New Zealand News

Sun, 26 May 2024
Panagora Asset Management Inc. Invests $236000 in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Tue, 21 May 2024
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 151 (M)
Shares Float 122 (M)
Held by Insiders 0.6 (%)
Held by Institutions 75.5 (%)
Shares Short 27,290 (K)
Shares Short P.Month 25,550 (K)
Stock Financials
EPS -0.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.22
Profit Margin -61.3 %
Operating Margin -13.9 %
Return on Assets (ttm) -18.5 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 17.1 %
Gross Profit (p.s.) 0
Sales Per Share 0.87
EBITDA (p.s.) -0.42
Qtrly Earnings Growth 0 %
Operating Cash Flow -43 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -6.28
PEG Ratio -0.4
Price to Book value -15.69
Price to Sales 3.93
Price to Cash Flow -11.98
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android